McDavid Stilwell - 13 Jun 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Reporting relationship: Chief Financial Officer
Issuer ticker: CHRS
Reported as of: 13 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2023, 16:40:33 UTC
Prior SEC filing: 04 Apr 2023
Next SEC filing: 03 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ McDavid Stilwell

Filing notes and source

Key filing fact

McDavid Stilwell filed Form 4 for Coherus BioSciences, Inc. (CHRS) on 15 Jun 2023.

Key facts

This page summarizes McDavid Stilwell's Form 4 filing for Coherus BioSciences, Inc. (CHRS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2023, 16:40.

Change

Previous filing in this sequence was filed on 04 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +70,000
Change %
Price: $0.000000
Shares after: 70,000
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,000
Exercise price: $5.44
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The underlying shares subject to the option vest and become exercisable as to 50% of the shares on each anniversary measured from June 13, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.